Status:
UNKNOWN
Salivary Biomarkers for Non-small Cell Lung Cancer Detection
Lead Sponsor:
PeriRx
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The investigators plan to recruit patients for a prospective study in patients in need of evaluation for lung lesions suspicious for cancer. Saliva samples will be collected before diagnostic evaluati...
Detailed Description
Consecutive eligible patients presenting to the study institutions and associated clinics will be enrolled. Inclusion and exclusion criteria are detailed separately in the section on eligibility. The ...
Eligibility Criteria
Inclusion
- Any patient presenting to the participating institutions of affiliated clinics for evaluation or biopsy of a lung lesion suspicious for cancer.
- Patients ≥ 18 years of age
- Patients willing and able to give informed consent
Exclusion
- Diagnosis of cancer within the last two years, excluding non-melanoma skin cancer (if \> 2 years since diagnosis, must be free of known disease \& not on current treatment for cancer).
- Prior immunosuppressive therapy or autoimmune disorder
- Known HIV infection
- Known Hepatitis infection
Key Trial Info
Start Date :
December 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2019
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT02294578
Start Date
December 1 2014
End Date
March 1 2019
Last Update
April 12 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
St. John Macomb-Oakland Hospital
Warren, Michigan, United States, 48093
2
Main Line Health Ststem
Wynnewood, Pennsylvania, United States, 19096